Sands Capital, an investment management company, released its “Sands Capital Select Growth Strategy” Q3 2025 investor letter.
Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...
At age 72, Nathan Harms still climbs ladders, hauls paint cans and balances on beams – tasks that demand precision, stamina ...
The healthcare industry presents a wealth of opportunities for investors to generate notable portfolio returns over decades.
MILWAUKEE, Nov. 24, 2025 /PRNewswire/ — Ademi & Fruchter LLP is investigating possible securities fraud claims against DexCom, Inc. (NASDAQ: DXCM). The investigation results from inaccurate statements ...
Adults with type 2 diabetes who used a continuous glucose monitor and wore their sensor for more than 270 days in 1 year had ...
Dexcom has announced that the Dexcom G7 15 Day Continuous Glucose Monitoring (CGM) System for people over the age of 18 with diabetes will launch in the United States on Dec. 1.
Explore Touchstone Sands Capital Select Growth Fund's Q3 2025 performance, AI strategy, and key holdings. Click here to ...
Touchstone Sands Capital Select Growth Fund Q3 review highlights AI-driven gains and challenges. Explore insights and ...
The figures show that preventing these complications alone could save more than $604 million in direct medical costs. CGMs ...
Medical Device Network on MSN
Abbott issues correction over incorrect FreeStyle Libre sensor readings
Abbott has initiated a medical device correction for sensors used in certain FreeStyle Libre 3 continuous glucose monitoring (CGM) systems in the US after determining that some of them may be ...
New data shows the introduction of publicly funded Continuous Glucose Monitors (CGMs) for people living with type 1 diabetes ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback